Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVES:
I. To assess tumor response to R-CyBor-D in patients with relapsed follicular (Gr 1 or 2), mantle cell, marginal zone lymphomas, small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and lymphoplasmacytic (Waldenstrom's macroglobulinemia) lymphoma.
SECONDARY OBJECTIVES:
I. To evaluate overall survival, progression-free survival, duration of response, and time to treatment failure of patients receiving R-CyBor-D.
II. To describe the adverse event profile (using National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v 3.0) of R-CyBor-D.
III. To evaluate quality of life for patient reported neurotoxicity using the Gynecologic Oncology Group's Functional Assessment of Cancer Therapy (FACT/GOG) neurotoxicity questionnaire, version 4.0.
OUTLINE:
Patients receive rituximab intravenously (IV) on day 1and cyclophosphamide orally (PO), bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3-6 months for up to 3 years.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Scottsdale、Arizona、美国、85259
- Mayo Clinic in Arizona
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Histological confirmation of relapsed or refractory follicular Grades 1 or 2 lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, or lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia/WM) by biopsy ≤ 6 months prior to registration
- NOTE: MCL diagnosis should be confirmed by cyclin D1 staining or fluorescence in situ hybridization (FISH) (t(11;14))
Measurable disease by computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) scans with lymph nodes ≥2.0 cm in at least one dimension or tumor cells in the blood ≥ 5 x10^9/L
- NOTE: Lymphoplasmacytic lymphoma (WM) patients without lymphadenopathy must have 1.) >10% lymphocytes, lymphoplasmacytic cells or plasma cells on a bone marrow aspirate/biopsy, and 2.) quantitative IgM ≥ 400mg/dL
- Expected survival > 3 months
- ECOG Performance Status (PS) 0, 1 or 2
- Absolute Neutrophil Count ≥ 1200
- Platelet ≥ 75000
- Hemoglobin ≥ 8.0 g/dL
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Alkaline phosphatase ≤ 3 x ULN
- Aspartate aminotransferase (AST) ≤ 3 x ULN
- Creatinine ≤ 1.5 x ULN
- Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of VELCADE (bortezomib), or agree to completely abstain from heterosexual intercourse
- Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse
- Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
- Willingness to return to Mayo Clinic institution for follow-up
- Negative serum pregnancy test done <7 days prior to registration, for women of childbearing potential only
- Willingness to complete questionnaires by themselves or with assistance
Exclusion Criteria:
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
- Pregnant women -- confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women;
- Nursing women;
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse event of the prescribed regimen
- Patients known to be human immunodeficiency virus (HIV) positive
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Diagnosed or treated for another malignancy ≤ 3 years prior to registration, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy
- NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
- Patient has received other investigational drugs ≤ 14 days prior to registration
- Patient has hypersensitivity to bortezomib, boron or mannitol
Myocardial infarction ≤ 6 months prior to registration or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- NOTE: Prior to study entry, any electrocardiogram (ECG) abnormality at Screening has to be documented by the investigator as not medically relevant
- Previous cancer therapy, hormonal therapy and surgery < 4 weeks prior to registration
- Patient has ≥ Grade 2 peripheral neuropathy
Radiation therapy within 3 weeks before randomization
- Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Treatment (R-CYBOR-D)
Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
|
鉴于IV
其他名称:
给定采购订单
其他名称:
给定采购订单
鉴于IV
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Proportion of Responses (Complete Response or Partial Response)
大体时间:up to 12 cycles
|
A response is defined to be a Complete Response (CR) or Partial Response (PR) noted as the objective status on any evaluation (i.e., best response).
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
A confidence interval for the true success proportion will be calculated according to the properties of the binomial distribution.
|
up to 12 cycles
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall Survival
大体时间:Up to 3 years from registration
|
Survival time is defined as the time from registration to death due to any cause.
The distribution of survival time will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from registration
|
Progression-free Survival
大体时间:Up to 3 years from registration
|
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression or death, whichever occurs first.
Progression is defines as having any new lesion or increase by 50% of previously involved sites from nadir.
The distribution of progression-free survival time will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from registration
|
Duration of Response
大体时间:Up to 3 years from registration
|
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented.
MR for Waldenstrom lymphoma will not be included as a response.
Median duration of response and the confidence interval for the median duration will be computed.
|
Up to 3 years from registration
|
Time to Treatment Failure
大体时间:Up to 3 years from registration
|
Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal.
If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment.
The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from registration
|
Adverse Events
大体时间:up to 12 cycles (28 days per cycle) of treatment
|
Adverse events were assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 after each cycle of treatment.
The maximum grade for each type of adverse event were recorded for each patient, and frequency tables were reviewed to determine patterns.
For this endpoint, the number of patients receiving a Grade 3, Grade 4, or Grade 5 as their highest reported grade regardless of attribution are reported.
A full list of adverse events are reported in the Adverse Events section of this report.
|
up to 12 cycles (28 days per cycle) of treatment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 病理过程
- 心血管疾病
- 血管疾病
- 免疫系统疾病
- 组织学类型的肿瘤
- 肿瘤
- 淋巴增生性疾病
- 淋巴系统疾病
- 免疫增生性疾病
- 淋巴瘤,非霍奇金
- 疾病属性
- 血液病
- 出血性疾病
- 止血障碍
- 副蛋白血症
- 血液蛋白失调
- 肿瘤,浆细胞
- 白血病、淋巴细胞
- 白血病
- 白血病,B细胞
- 淋巴瘤,B细胞
- 淋巴瘤
- 淋巴瘤,滤泡性
- 复发
- 淋巴瘤,套细胞
- 淋巴瘤、B 细胞、边缘区
- 华氏巨球蛋白血症
- 白血病、淋巴细胞性、慢性、B 细胞
- 药物的生理作用
- 药理作用的分子机制
- 自主代理
- 周围神经系统药物
- 抗炎药
- 抗风湿药
- 抗肿瘤药
- 免疫抑制剂
- 免疫因素
- 止吐药
- 胃肠道药物
- 糖皮质激素
- 荷尔蒙
- 激素、激素替代品和激素拮抗剂
- 抗肿瘤药,激素
- 抗肿瘤药,烷基化
- 烷化剂
- 清髓性激动剂
- 抗肿瘤药,免疫学
- 地塞米松
- 环磷酰胺
- 利妥昔单抗
- 硼替佐米
其他研究编号
- MC0883 (其他标识符:Mayo Clinic)
- P30CA015083 (美国 NIH 拨款/合同)
- NCI-2011-02991 (注册表标识符:CTRP (Clinical Trial Reporting Program))
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
利妥昔单抗的临床试验
-
Aprea Therapeutics终止套细胞淋巴瘤 | 慢性淋巴细胞白血病 | 非霍奇金淋巴瘤美国
-
Memorial Sloan Kettering Cancer Center完全的